Table 4.
Previous GH treatment, body composition, and glucose tolerance in pubertal girls with TS
| GH (27) | No GH (8) | P | |
|---|---|---|---|
| Age (yr) | 17.4 ± 2.4 (13–21) | 16.9 ± 3.5 (15–19) | 0.5 |
| BMI (kg/m2) | 24.4 ± 3.8 | 30.7 ± 5.3 | 0.01a |
| BF (%) | 33.7 ± 1.8 | 39.5 ± 3.4 | 0.03b |
| SAT (ml)c | 142.5 ± 22.4 | 313.8 ± 75.6 | <0.0001b |
| VAT (ml)c | 36.1 ± 4.1 | 75.3 ± 13.8 | <0.0001b |
| Fasting insulin (μIU/ml) | 7.3 ± 2.8 | 12.5 ± 4.4 | 0.005b |
| IAUC (IU/min·ml) | 9.9.1 ± 2.9 | 17.3 ± 4.2 | 0.0001b |
These girls had all discontinued GH or were never on GH. Data are means ± se. The number of GH-treated girls in Tables 3 and 4 does not equal 76 because some were still on GH during puberty (either spontaneous or estrogen treated, n = 10) and some had discontinued GH but not started estrogen (n = 3). P values for SAT, VAT, fasting insulin, and incremental area under the curve for insulin (IAUC) remain significant at <0.008 after the Bonferroni correction.
Group means were compared by ANCOVA including age as covariate.
Group means were compared by ANCOVA including age and BMI as covariates.
Twenty-three GH-treated and six untreated girls had MRI abdominal fat measurements.